Literature DB >> 15944410

Thrombomodulin enhances the invasive activity of mouse mammary tumor cells.

Shingo Niimi1, Mizuho Harashima, Kazuko Takayama, Mayumi Hara, Masashi Hyuga, Taiichiro Seki, Toyohiko Ariga, Toru Kawanishi, Takao Hayakawa.   

Abstract

Thrombomodulin (TM) is a thrombin receptor on the surface of endothelial cells that converts thrombin from a procoagulant to an anticoagulant. Thrombin promotes invasion by various tumor cells, and positive or negative correlations are found between the expression of TM and tumorigenesis in some patients. In this study, we used an invasion assay to investigate the effect of TM on the invasive activity of a mouse mammary tumor cell line, MMT cells, and the effects of TM were compared with those of thrombin as a positive control. In the presence of 1% fetal calf serum (FCS), TM significantly stimulated MMT cell invasion in a dose-dependent manner, resulting in an approximately 3-fold increase at 1-10 pg/ml over the untreated control. Thrombin also caused a similar degree of stimulation at 50 ng/ml. Since thrombin activity was detected in the components of the assay system, an invasion assay was also performed in a thrombin-activity-depleted assay system constructed to eliminate the effect of thrombin activity; TM (10 pg/ml) plus thrombin (1 pg/ml) stimulated invasion by approximately 3.5-fold in this assay system. Hirudin, a specific thrombin inhibitor, inhibited stimulation by TM as well as by thrombin in both the presence and absence of 1% FCS. Investigations of the effects of TM on proliferation, adhesion and chemotaxis to clarify the mechanism of stimulation by TM revealed that TM does not affect proliferation or adhesion in the presence of 1% FCS, but stimulates chemotaxis by approximately 2.3-fold. Similar results were obtained in experiments using thrombin. TM (10 pg/ml) plus thrombin (1 pg/ml), on the other hand, stimulated chemotaxis by approximately 2.3-fold in the thrombin-activity-depleted assay system. Binding studies using [125I]-thrombin revealed that the cells have specific saturable binding sites for thrombin. These results show that TM stimulates the invasive activity of MMT cells, probably by acting as a cofactor for the thrombin-stimulated invasion of the cells via its receptor and lowering the effective concentration of thrombin. The findings also indicate that the stimulation of invasive activity in the presence of 1% FCS and in the thrombin-activity-depleted assay system may mainly be mediated by the stimulation of chemotaxis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944410     DOI: 10.1093/jb/mvi070

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  3 in total

1.  Thrombomodulin mediates the migratory ability of hormone-independent prostate cancer cells through the regulation of epithelial-to-mesenchymal transition biomarkers.

Authors:  Chun-Te Wu; Yu-Jia Chang; Miao-Fen Chen; Jun-Jen Liu; Po-Li Wei; Weu Wang; Hui-Hsiung Liu
Journal:  Tumour Biol       Date:  2014-03-15

2.  Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain.

Authors:  Netanel A Horowitz; Elizabeth A Blevins; Whitney M Miller; Ashley R Perry; Kathryn E Talmage; Eric S Mullins; Matthew J Flick; Karla C S Queiroz; Kun Shi; C Arnold Spek; Edward M Conway; Brett P Monia; Hartmut Weiler; Jay L Degen; Joseph S Palumbo
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

3.  Thrombomodulin modulates cell migration in human melanoma cell lines.

Authors:  Andreia da Silva de Oliveira; Likiu Yang; Juliana Echevarria-Lima; Robson Q Monteiro; Alireza R Rezaie
Journal:  Melanoma Res       Date:  2014-02       Impact factor: 3.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.